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Background. Mass distributions of oral azithromycin have long been used to eliminate trachoma, and they are now being pro-
posed to reduce childhood mortality. The observed benefit appears to be augmented with each additional treatment, suggesting a 
possible community-level effect. Here, we assess whether 2 biannual mass treatments of preschool children affect the community’s 
gut microbiome at 6 months after the last distribution.
Methods. In this cluster-randomized controlled trial, children aged 1–60 months in the Dossa region of Niger were randomized 
at the village level to receive a single dose of azithromycin or placebo every 6 months. Fecal samples were collected 6 months after 
the second treatment for metagenomic deep sequencing. The prespecified primary outcome was the Euclidean PERMANOVA of the 
gut microbiome, or effectively the distance between the genus-level centroid at the community level, with the secondary outcome 
being the Simpson’s α diversity.
Results. In the azithromycin arm, the gut microbial structures were significantly different than in the placebo arm (Euclidean 
PERMANOVA, P < .001). Further, the diversity of the gut microbiome in the azithromycin arm was significantly lower than in the 
placebo arm (inverse Simpson’s index, P = .005).
Conclusions. Two mass azithromycin administrations, 6 months apart, in preschool children led to long-term alterations of the 
gut microbiome structure and community diversity. Here, long-term microbial alterations in the community did not imply disease 
but were associated with an improvement in childhood mortality.
Clinical Trials Registration. NCT02048007.
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Azithromycin is a broad-spectrum bacteriostatic macrolide 
with a long half-life and excellent tissue penetration [1]. The 
drug has been used extensively for the treatment of respiratory, 
enteric, and genitourinary infections [1]. In addition, the World 
Health Organization has recommended mass oral azithromycin 
treatment as part of an effort to eliminate blinding trachoma 
[2–4], and >700 million doses of azithromycin have been dis-
tributed for this purpose. Other uses are now being proposed, 
including to improve childhood mortality.
Macrolides Oraux pour Réduire les Décès avec un Oeil sur la 
Résistance (MORDOR; clinical trial registration NCT02048007) 
was a large double-masked, cluster-randomized controlled trial 
that took place between 2015 and 2017 in 3 countries: Niger, 
Malawi, and Tanzania. This trial found a significant 18% reduc-
tion in childhood mortality with mass azithromycin adminis-
trations in Niger [5].The mechanism of mortality reduction is 
not clear, although the functional state of the gut microbiome 
has been linked in numerous ways to a child’s health and dis-
ease [6]. Its microbial composition, diversity, and intestinal 
pathogen abundances can be significantly altered for days to 
weeks after systemic antibiotic administration [7–10]. Longer-
term persistence of the individual treatment and its functional 
effects, however, have been difficult to demonstrate. Here, we 
tested whether the gut microbiome in preschool children was 
affected 6 months after the previous antibiotic distribution in 
the relatively antibiotic-naïve, high–childhood mortality setting 
of Niger.
METHODS
Study Setting and Design
We obtained ethical approval for the study from the University 
of California San Francisco (UCSF) Committee for Human 
Research and the Ethical Committee of the Niger Ministry of 
Health (Institutional Review Board No. 10-01036). The study was 
undertaken in accordance with the Declaration of Helsinki. This 
study was a double-masked, cluster randomized controlled clinical 
trial with a prespecified primary outcome conducted in Niger. In 
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Niger, 594 villages were randomized to receive 1 oral administra-
tion of azithromycin (Pfizer, New York, NY; height-based dosing to 
roughly 20 mg/kg) or placebo every 6 months for 2 years (Figure 1). 
Thirty communities were randomly selected for close monitoring, 
including the collection of rectal swabs from children. Baseline 
demographics of these 30 communities are displayed in Table 1.
The randomization sequence was generated by T.C.P.  and 
implemented by T.C.P., K.J.R., and Pfizer personnel (necessary 
for packaging). Allocation concealment was attained by assigning 
communities simultaneously. Trained study personnel directly 
observed both antibiotic and placebo being taken by study sub-
jects. We obtained oral consent from guardians of children before 
treatment distribution. No incentives were offered for participation 
of this study. The prespecified primary outcome was the Euclidean 
PERMANOVA P value for differences in the gut microbiome 
between treatment groups at the 12-month time point. We antic-
ipated that the inclusion of 30 communities and a pooled sam-
ple from 10 children per community would provide 80% power 
to detect a mean 0.75 SD difference in within-group L2-norm 
(Euclidean) distance from between-group distance. Similarly, 
30 communities would provide 80% power to detect a 0.75-SD 
decrease in alpha diversity using an inverse Simpson’s index.
Sample Processing and Sequencing
Rectal samples were collected in the field at 12 months (6 months 
after the second treatment). For each study participant, examiners 
changed into clean gloves, placed the swab 1–3 cm into the anus 
and rotated 360 degrees, repeating until stool was visible on 
the swab. Swabs were immediately placed into a Stool Nucleic 
Acid Collection and Transport Tube containing Norgen Stool 
Preservative (Norgen, Ontario, Canada). Samples were immedi-
ately placed on ice in the field and transported to the study center 
for storage at –20°C while in Niger and shipped to UCSF for long-
term storage at –80°C. Samples were de-identified. Researchers 
performing the assays were masked. Ten samples from each village 
were randomly chosen for pooling and subsequent library prepa-
ration and sequencing (Figure 1). RNA was extracted from 300 
fecal samples using the Norgen Stool RNA Isolation Kit (Norgen, 
Ontario, Canada), per the manufacturer’s instructions. The RNA 
concentration of each sample was quantified using the Qubit RNA 
HS Assay Kit (ThermoFisher Scientific, Waltham, MA) and nor-
malized for pooling. The RNA from the 300 samples was pooled 
into 30 samples (10 samples per village). Five microliters of the 
pooled RNA was used to prepare libraries using the New England 
Biolabs’ (NEB’s) NEBNext RNA First Strand Synthesis Module 
(E7525) and NEBNext Ultra Directional RNA Second Strand 
Synthesis Module (E7550) to generate double-stranded cDNA. 
The cDNA was converted to Illumina libraries using the NEBNext 
Ultra II DNA Library Prep Kit (E7645) according to the manufac-
turer’s recommendation and then amplified with 14 polymerase 
chain reaction cycles. Samples were sequenced on the Illumina 
HiSeq 4000 using 125-nucleotide (nt) paired-end sequencing.
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Figure 1. Trial profile. Children aged 1–60 months, from 30 villages, were randomly assigned to either the placebo or azithromycin-treated groups. Rectal samples from 10 
children in each village were pooled and subjected to metagenomic RNA sequencing and analysis.
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Metagenomic Sequencing Analyses and Statistical Methods
An initial human-sequence removal step was accomplished by 
alignment of all paired-end reads to the human reference genome 
38 (hg38) and the Pantroglodytes genome (panTro4, 2011, UCSC), 
using the Spliced Transcripts Alignment to a Reference (STAR) 
aligner (v. 2.5.1b) [11]. Unaligned reads were quality-filtered using 
PriceSeqFilter with the “-rnf 90” and “-rqf 85 0.98” settings [12]. 
Reads that passed quality control were then subjected to dupli-
cate removal. The remaining reads that were at least 95% identical 
were compressed by cd-hit-dup (v. 4.6.1) [13]. Paired reads were 
then assessed for complexity by compression with the Lempel-
Ziv-Welch algorithm [14]. Read pairs with a compression space 
savings score lower than 0.45 were removed. Another round of 
human reads removal was performed using the very-sensitive-lo-
cal mode of Bowtie2 (v. 2.2.4) with the same hg38 and panTro4 
reference genomes described above [15]. The remaining nonhost 
read pairs were then passed onto Centrifuge (v. 1.0.3) to align 
to the entire NCBI nonredundant collection, downloaded on 
February 28, 2016 [16]. This reference database contains com-
pleted genomes, draft genomes, and partial genomes. Overall, it 
comprises ~75 000 genera, including many eukaryotes.
The primary outcome of this study was conducted on the 
pooled samples. Specifically, we used PERMANOVA to com-
pare within-group and between-group Euclidean distances 
among samples [17]; significance was evaluated by a permu-
tation test that compares true distances with the distribution 
when assigned to groups by chance. The primary outcome was 
prespecified to capture any differences in the structure of the 
gut microbial communities between treatment groups. The sec-
ondary outcome was the alpha diversity (inverse Simpson’s) at 
the genus level of the microbiome of children within villages at 
12 months. As a diversity measure, Simpson’s index is weighted 
toward the abundant taxonomic groups in a population [18]. 
Therefore, as a sensitivity analysis, we also computed Shannon’s 
alpha diversity, a measure that is relatively more influenced 
by rare taxonomic groups in a population. Alpha and gamma 
diversities (Simpson’s and Shannon’s) were each assessed using 
equations described by Jost [18, 19]. We computed the difference 
in means of diversities by arm, that is, D= -a aplacebo abx . The 
permutation based P values for testing H0 0:D=  were com-
puted as the proportion of permutations with D  larger than the 
observed D  value for n = 10 000. Analyses were implemented 
in the R software environment (http://cran.r-project.org/), ver-
sion 3.1.3, package ‘vegetarian.’
RESULTS
Treatment with azithromycin resulted in a significant change 
in the bacterial gut microbiome composition. Specifically, the 
stool bacterial communities treated with azithromycin were 
significantly closer to each other (smaller Euclidean distance 
within groups) than they were to those in placebo communi-
ties (P < .001) (Figure 2A, Table 2) at 12 months. This result 
remained unchanged when the Euclidean distance was used 
for all taxa including nonbacterial (P < .001). This is consist-
ent with expectations, as the predominant fraction of the gut 
flora is bacterial (Figure 2B) and the main effect of azithromy-
cin is antibacterial [1, 20, 21]. Indeed, PERMANOVA analysis 
limited to other taxonomic groups did not reveal statistically 
significant differences between treatment arms (Table 2).
A prespecified secondary analysis of this study was the com-
munity-level (alpha) bacterial diversity (inverse Simpson’s). 
Here, we found that the inverse Simpson’s diversity index was 
decreased in the azithromycin arm (9.1; 95% CI, 7.8–10.8) com-
pared with the placebo arm (12.4; 95% CI, 11.5–13.4, P = .005) 
(Figure  2C). Similarly, Shannon’s diversity was reduced after 
azithromycin treatment (22.2; 95% CI, 19.9–25.1) compared with 
placebo (26.7; 95% CI, 25.2–28.3; P = .01) (Figure 2D, Table 3). 
To evaluate the richness in each treatment group, we compared 
the gamma diversity, which showed that the diversity was sig-
nificantly higher in the placebo arm compared with the azithro-
mycin arm (Table 3). These results demonstrate that 2 biannual 
administrations of single-dose azithromycin to all preschool chil-
dren are sufficient to induce long-lasting (at least 6 months’ dur-
ation) alterations in the gut microbiome at the community level.
DISCUSSION
Generally, a reduction in the gut microbiome diversity at the 
individual level has been associated with a pathologic state, 
ranging from Clostridium difficile colitis to the development of 
obesity and diabetes [22–24]. This study illustrates that such an 
association does not hold at the community level. Here, mass 
azithromycin distribution was associated with a community 
reduction in gut microbiome diversity, and in the companion 
mortality study of communities drawn from the same over-
all pool, the same treatment was associated with a significant 
improvement in childhood mortality [5]. The exact mecha-
nisms by which an alteration in the gut microbiome at the com-
munity level may lead to a reduction in childhood deaths in 
Table 1. Baseline Characteristics
Children Aged 0–60 mo Placebo, Mean (95% CI) Azithromycin, Mean (95% CI) P Valuea
Age, mo 33.9 (32.9–34.9) 31.5 (30.6–32.4) .30
Female, % 54.0 (51.2–56.7) 48.0 (45.8–50.2) .36
Abbreviation: CI, confidence interval; mo, months.
aWilcoxon rank-sum test for continuous variables and Fisher exact test for categorical variables.
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Niger are unclear. Respiratory infections, diarrhea, and malaria 
are among the major causes of childhood mortality in sub-Sa-
haran African countries [25–27]. Given that there is mounting 
evidence to support the role of the gut microbiome in modu-
lating the immune system [28, 29], it is possible that changes in 
the gut microbiome community in these children made them 
less susceptible to infections. At 12 months, however, we could 
not demonstrate that the protective effect of azithromycin 
was due to the reduction of intestinal pathogens. It remains to 
be seen if there will be a reduction in malaria or respiratory 
infections in the MORDOR trial. Most likely, multiple mecha-
nisms are contributing to the reduction in childhood mortality.
Several limitations apply to the interpretation of this study. 
Relatively antibiotic-naïve communities, like those in this study, 
have become exceedingly rare in the antibiotic era. Further, with 
the exception of mass drug distribution, coordination of antibiotic 
treatment to every preschool child in a community simply does not 
happen in the developing or developed countries. Also, because the 
rectal samples were pooled for sequencing, alterations in the gut 
microbiome can only be applied to changes at the community level. 
Given these limitations, we cannot generalize our findings to regions 
with greater background antibiotic use or lower childhood mortality.
In summary, two mass biannual azithromycin administrations 
in preschool children led to long-term alterations of the gut micro-
biome structure and community diversity. This same treatment 
resulted in a reduction in pediatric deaths. Determining the exact 
molecular mechanism(s) of azithromycin’s effect on mortality may 
help clarify possible large-scale implementation.
Acknowledgments
We thank Derek Bogdanoff in the UCSF Center for Advanced Technology 
for his expertise and assistance operating the Illumina sequencer.
Table 2. Difference in Gut Microbiome Between Treatment Groups
Taxonomic Group Euclidean Distance, P Value Manhattan Distance, P Value
All <.001 <.001
Bacteria <.001 <.001
Fungi .85 .94
Viruses .93 .83
Nematoda .26 .08
Plathelminth .97 .97
Ciliophora .16 .14
Apicomplexa .58 .60
Amoebozoa .17 .20
Significant P values are bolded.
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Figure 2. Two biannual treatments of azithromycin cause long-term alterations of the gut microbial communities of children. A, Principal coordinate analyses of the 
Euclidean distances for the placebo (gray) and the azithromycin-treated (orange) villages. Beta-dispersions were similar (P = .20) between treatment groups. B, Stacked bar 
graph of the abundance of the different taxonomic groups. Distributions of the inverse Simpson’s diversity index (C) and Shannon’s diversity index (D) for the placebo and 
azithromycin-treated villages. Abbreviation: PCoA, principal coordinate.
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Table 3.  Bacterial Diversity by Treatment Groups at 12 Months
Diversity
Placebo  
Effective Number 
(95% CI)
Azithromycin  
Effective Number 
(95% CI) P  Valuea
Alpha Simpson 
(inverse)
12.4 (11.5–13.4) 9.1 (7.8–10.8) .005
Shannon  
(exponential: eH’)
26.7 (25.2–28.3) 22.2 (19.9–25.1) .01
Gamma Simpson 
(inverse)
15.5 (14.1–16.3) 10.5 (8.9–12.7) .003
Shannon  
(exponential: eH’)
32.2 (30.0–33.2) 26.9 (23.4–30.2) .03
Alpha and gamma diversity indices were calculated for each treatment group, as described 
by Jost [18, 19].
Abbreviation: CI, confidence interval.
aPermutation-based P values.
